share_log

Predictmedix AI Rolls Out Advanced AI-Powered Safe Entry Stations at Trinity Hospital

Predictmedix AI Rolls Out Advanced AI-Powered Safe Entry Stations at Trinity Hospital

Predictmedix AI 在三一醫院推出先進的人工智能安全入口站
Accesswire ·  02/07 20:30

First deployment in Northeast India to serve as showcase for 8 Northeastern states

首次在印度東北部部署,爲東北8個州提供示範

Revenue generating with potential for significant expansion

創收具有顯著擴張潛力

TORONTO, ON / ACCESSWIRE / February 7, 2024 / Predictmedix AI Inc. (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP) (the "Company" or "Predictmedix"), a leading provider of rapid health screening solutions powered by proprietary artificial intelligence (AI), today announced that its state-of-the-art AI-driven Safe Entry Stations will be deployed at Trinity Hospital, Mizoram, India. This strategic initiative aims to revolutionize the screening process for vitals and mental health. Moreover, this sets the stage for broader deployment across privately held hospitals in Northeastern states. This is the company's first deployment in Northeast India which will also serve as a showcase for 8 North Eastern States in India.

安大略省多倫多/ACCESSWIRE/2024年2月7日/由專有人工智能(AI)提供支持的快速健康篩查解決方案的領先提供商Predictmedix AI Inc.(CSE: PMED)(OTCQB: PMED)(FRA: 3QP)(“公司” 或 “Predictmedix”)今天宣佈,其最先進的人工智能驅動安全入境站將部署在印度米佐拉姆三一醫院。這項戰略計劃旨在徹底改變生命和心理健康篩查流程。此外,這爲在東北各州的私營醫院進行更廣泛的部署奠定了基礎。這是該公司在印度東北部的首次部署,也將作爲印度東北8個州的展示平台。

Northeast India, encompassing eight states-Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, and Sikkim-houses a population exceeding 50 million. This region represents a significant demographic and strategic area, poised for transformative healthcare advancements and economic growth.

印度東北部包括八個州——阿魯納恰爾邦、阿薩姆邦、曼尼普爾邦、梅加拉亞邦、米佐拉姆邦、那加蘭邦、特里普拉邦和錫金邦,人口超過5000萬。該地區是一個重要的人口和戰略區域,有望實現變革性的醫療保健進步和經濟增長。

This deployment marks Predictmedix AI's commitment to advancing healthcare solutions by introducing cutting-edge technology to facilitate efficient and securely screening process in healthcare for vitals as well as mental health. The approach involves the implementation of AI-driven Safe Entry Stations at Trinity Hospital and a planned expansion to other privately held hospitals in Northeastern states of India, targeting improved health and safety measures.
The impact of this deployment is multifaceted, encompassing not only the generation of revenue through the implementation of Safe Entry Stations but also solidifying Predictmedix AI's position as a pivotal entity in driving transformative healthcare solutions within the region. In addition, the partnership model with Trinity Hospital, a private healthcare institution, includes a revenue-sharing agreement where 70 percent of the revenue generated from each patient screened by the AI-Powered Safe Entry Stations will be allocated to Predictmedix AI. This arrangement not only underscores the financial viability of the deployment but also highlights the potential for substantial revenue growth as the technology is adopted across additional healthcare facilities.
"We are excited to bring our AI-powered Safe Entry Stations to Trinity Hospital, enhancing their triage capabilities," commented Rahul Kushwah, COO of Predictmedix AI. " This strategic deployment not only serves the immediate needs of Trinity Hospital but also lays the groundwork for a comprehensive expansion across Northeastern India, showcasing our commitment to advancing health and safety measures.
Predictmedix AI's Safe Entry Stations utilize advanced artificial intelligence for quick and reliable health assessments, contributing to a safer and more streamlined triage process. The company looks forward to working closely with Trinity Hospital and other healthcare institutions in the region, providing innovative solutions to meet the evolving challenges in healthcare.

此次部署標誌着Predictmedix AI致力於通過引入尖端技術來促進醫療保健領域高效、安全的生命和心理健康篩查流程,從而推進醫療保健解決方案的發展。該方法涉及在三一醫院實施人工智能驅動的安全入境站,並計劃擴展到印度東北部各州的其他私人醫院,旨在改善健康和安全措施。
此次部署的影響是多方面的,不僅包括通過實施安全入境站創造收入,還鞏固了Predictmedix AI作爲推動該地區變革性醫療解決方案的關鍵實體的地位。此外,與私人醫療機構三一醫院的合作模式包括一項收益分享協議,根據該協議,由人工智能驅動的安全入境站篩查的每位患者產生的收入的70%將分配給Predictmedix AI。這種安排不僅突顯了部署的財務可行性,還凸顯了隨着該技術在其他醫療機構中得到採用,收入大幅增長的潛力。
Predictmedix AI首席運營官拉胡爾·庫什瓦評論說:“我們很高興將人工智能驅動的安全入口站引入三一醫院,增強他們的分診能力,這種戰略部署不僅滿足了三一醫院的迫切需求,而且爲印度東北部的全面擴張奠定了基礎,表明了我們對推進健康和安全措施的承諾。
Predictmedix AI的安全入境站利用先進的人工智能進行快速可靠的健康評估,從而爲更安全、更簡化的分診流程做出了貢獻。該公司期待與三一醫院和該地區的其他醫療機構密切合作,提供創新的解決方案,以應對醫療保健領域不斷變化的挑戰。

To receive company news, please sign up for alerts at the bottom of the page link below:

要接收公司新聞,請在頁面底部註冊接收提醒,鏈接如下:

About Predictmedix AI Inc.

關於 Predictmedix AI Inc.

Predictmedix AI Inc. (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at or follow us on Twitter, Instagram or LinkedIn.

Predictmedix AI Inc.(CSE:PMED)(場外交易代碼:PMEDF)(FRA: 3QP)是全球快速健康篩查和遠程患者護理解決方案的新興提供商。該公司的安全入境站由專有的人工智能(AI)提供支持,使用多光譜攝像機分析生理數據模式並預測各種健康問題,包括19種生理生命參數、藥物或酒精損害、疲勞或各種精神疾病。Predictmedix AI 專有的遠程患者護理平台爲醫療專業人員提供了一套人工智能驅動的工具,以改善患者的健康狀況。要了解更多信息,請訪問我們的網站或在推特、Instagram或領英上關注我們。

Public Relations Contact

公共關係聯繫人

For further media information or to set up an interview, please contact:

欲了解更多媒體信息或安排採訪,請聯繫:

Nelson Hudes

納爾遜·哈德斯

Communications International (905) 660 9155

通信國際 (905) 660 9155

Nelson@hudescommunications.com

Nelson@hudescommunications.com

Dr. Rahul Kushwah (647) 889 6916

Rahul Kushwah 博士 (647) 889 6916

Caution Regarding Forward-Looking Information:

關於前瞻性信息的注意事項:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

本新聞稿可能包含前瞻性陳述和基於當前預期的信息。這些陳述不應被視爲對公司未來業績或業績的保證。此類陳述涉及已知和未知的風險、不確定性和其他因素,這些因素可能導致實際業績、業績或成就與此類陳述所暗示的結果存在重大差異。儘管此類陳述基於管理層的合理假設,但無法保證此類假設會被證明是正確的。我們不負責更新或修改它們以反映新的事件或情況。公司的證券尚未根據經修訂的1933年《美國證券法》(“美國證券法”)或適用的州證券法進行註冊,如果沒有註冊或不受此類註冊要求的適用豁免,則不得向在美國的人或 “美國個人”(該術語的定義見美國證券法的法規)發行或出售,也不得爲他們的賬戶或利益發行或出售。本新聞稿不構成出售要約或招攬買入要約,也不得在美國或任何此類要約、招攬或出售非法的司法管轄區出售證券。此外,還有一些已知和未知的風險因素可能導致公司的實際業績、業績或成就與本文件所含前瞻性信息所表達或暗示的未來業績、業績或成就存在重大差異,例如但不限於依賴獲得監管部門批准;獲得與其技術相關的知識產權的能力;運營歷史有限;一般商業、經濟、競爭、政治、監管和社會不確定性,以及特別是與 COVID-19 相關的不確定性;與公司無法控制的因素相關的風險,包括與 COVID-19 相關的風險;與公司股票相關的風險,包括該方可能也可能無法控制的事件導致的價格波動;對管理層的依賴;以及該行業其他競爭對手的緊急情況。

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

本文中的所有前瞻性信息均受本警示聲明的全面限制,除非法律要求,否則公司不承擔任何修改或更新任何此類前瞻性信息或公開宣佈爲反映未來業績、事件或發展而對本文包含的任何前瞻性信息進行任何修訂的結果的義務。

Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

免責聲明:“公司目前並未明確或暗示其產品有能力診斷、消除、治癒或遏制 COVID-19(或 SARS-2 冠狀病毒)。

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

加拿大證券交易所尚未審查本新聞稿的充分性或準確性,也不承擔任何責任。

SOURCE: Predictmedix AI Inc.

來源:Predictmedix AI Inc.


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論